Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 92. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Adaora “Ada” Alise Adimora1547
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis1371
Highlights from the sixth ESCMID Conference on Vaccines1034
DNDi receives Dutch funding boost685
HIV vaccine trial failure586
Research in brief583
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum504
COVID-19 vaccination protects children and adolescents419
Environment and infectious diseases397
Promoting diversity and equity in publishing374
A step forward in the journey towards hookworm vaccines359
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7332
Listeria monocytogenes: a rare, deadly cause of peritonitis313
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations301
Updated criteria for paediatric sepsis and septic shock288
Infectious disease surveillance update287
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges281
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation272
Surge of cutaneous leishmaniasis in Pakistan268
Reflecting on lessons from the 2014–16 Ebola virus outbreak267
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations266
The next chapter for Africa's genomic initiatives257
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic242
The lasting lessons of mpox: infection, vaccination, and immune memory229
Attention to skin-related neglected tropical diseases216
Shaping opportunities for future clinical trials in tuberculosis211
Ivan Hirsch208
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting195
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study194
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study194
Kyasanur Forest disease: an emerging arboviral threat192
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1191
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial185
The superiority of bivalent over monovalent booster vaccines183
Threat of HIV and tuberculosis drug resistance after US funding cuts182
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 177
Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, sing167
A patient with secondary syphilis following incomplete treatment of primary infection160
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C158
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial151
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria149
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review146
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial146
Measles immunity gaps and outbreak risk in a shifting landscape145
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom144
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis143
Best practice guidelines for viral hepatitis service delivery in prisons142
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial142
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study141
GoGoVax dispels hopes for gonorrhoea vaccination141
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden141
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer140
Correction to Lancet Infect Dis 2025; 25: e280–93138
Correction to Lancet Infect Dis 2020; 20: 60–79138
New UN resolution links NTDs to human rights136
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect134
Mpox in people with past infection or a complete vaccination course: a global case series132
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco131
New flavours of tuberculosis treatment for children127
Research in brief127
Research in brief127
A new monoclonal in the arMAMentarium against malaria126
Global cholera resurgence—a preventable tragedy124
The implications of mpox breakthrough infections on future vaccination strategies122
Theresa Ochoa—staying on top of infectious diseases in Peru119
Research in brief117
RSV prevention: public health lessons from the southern hemisphere115
Full-dose NSAIDs at the first sign of respiratory infection?113
Tuberculosis recovery in Georgia: implementing more by 24110
Election of Regional Director for the Western Pacific109
Emil Gotschlich109
Serpiginous-like choroiditis in ocular tuberculosis107
Supporting healthcare access for refugees and migrants107
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86105
Infectious disease surveillance update105
COVID-19 mortality in Africa and Asia – Authors' reply104
High-dose primaquine reduces vivax relapses: time for change104
Elisabeth Presterl—always looking forward103
Research in brief102
The response of mpox-associated inflammatory syndrome to steroid therapy102
Immune evasiveness of SARS-CoV-2 variants and vaccine selection101
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe100
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa100
Curing chronic hepatitis B virus infection98
Addressing the shortage of cholera vaccines98
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply97
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance97
Patient-centred approaches for drug-resistant tuberculosis97
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-096
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-295
Correction to Lancet Infect Dis 2023; 23: e46995
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-593
0.75853300094604